sorafenib has been researched along with Hepatitis B in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (14.29) | 29.6817 |
| 2010's | 25 (71.43) | 24.3611 |
| 2020's | 5 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, F; He, H; Li, H; Quan, Y; Zhou, J | 1 |
| Abdelaziz, AO; Abou-Alfa, GK; Afihene, M; Agyei-Nkansah, AA; Alatise, OI; Ali, MM; Asombang, A; Atipo Ibara, BI; Balogun, F; Biachi de Castria, T; Bougouma, A; Bounedjar, A; Capanu, M; Chou, JF; Cunha, L; Diop, PS; El Baghdady, N; Elwakil, R; Fouad, M; Hammad, N; Jonas, E; Kimani, S; Kingham, P; Kurrimbukus, R; Li, Y; Makondi, PT; Mekonnen, HD; Ndlovu, N; Ndumbalo, J; Roberts, LR; Servais Albert Fiacre, EB; Sewram, V; Spearman, CW; Tzeuton, C; Yang, JD | 1 |
| Chang, CS; Lee, SW; Lee, TY; Peng, YC; Yang, SS; Yeh, HZ | 1 |
| Cheng, S; Du, C; Fan, X; Fu, J; Gao, Y; Li, N; Ma, J; Markowitz, GJ; Qin, W; Wang, H; Yang, B; Yang, P | 1 |
| Burns, MC; Fenton, SE; Kalyan, A | 1 |
| Bai, Y; Cang, S; Chen, M; Chen, Y; Chen, Z; Cui, J; Du, C; Fan, J; Gao, Z; Gu, S; Guo, Y; Huang, M; Jia, W; Li, Q; Liu, B; Liu, C; Lu, Y; Mao, Y; Meng, Z; Qin, Y; Ren, Z; Shan, Y; Shao, G; Shi, X; Teng, G; Wang, J; Wang, Y; Wu, J; Xia, F; Xing, B; Xu, A; Xu, J; Yang, W; Yang, Y; Yin, G; Yin, T; Zhang, B; Zhou, H | 1 |
| Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS | 1 |
| Arakawa, Y; Bando, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Teraoku, H; Yoshimoto, T | 1 |
| Dong, W; Guo, XG; He, XD; Liu, FC; Liu, H; Wang, ZH | 1 |
| Amanuma, M; Daido, Y; Higai, K; Igarashi, Y; Kobayashi, K; Matsui, D; Matsui, T; Matsukiyo, Y; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Shinohara, M; Wakui, N; Yoshimine, N | 1 |
| Anderson, J; Chao, Y; Choo, SP; Chopra, A; Cruz, CD; Hou, MM; Hsu, C; Ikeda, M; Kang, YK; Kim, TY; Kudo, M; Kuromatsu, R; Moriguchi, M; Numata, K; Yau, T; Yeo, W; Zhao, H | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 2 |
| Anand, BS; Fitzmorris, P; Shoreibah, M; Singal, AK | 1 |
| Chan, SY; Cheng, AL; Hsu, CH; Lu, LC; Shao, YY; Shau, WY | 1 |
| Chen, M; Gao, H; Huang, J; Li, S; Wang, H; Xu, L; Zhang, Y; Zhou, Z | 1 |
| Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Yoo, BC | 1 |
| Chen, DS; Chen, KF; Chen, PJ; Lin, WH; Shiau, CW; Teng, YC; Tsai, TF; Wang, SH; Yeh, SH | 1 |
| Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J | 1 |
| Fu, P; Li, Q; Wen, F; Wheeler, J; Yang, Y; Zhang, P | 1 |
| Bi, XY; Cai, JQ; Han, Y; Huang, Z; Li, H; Li, MX; Li, ZY; Yao, XS; Zhang, YF; Zhao, DB; Zhao, H; Zhao, JJ; Zhou, JG | 1 |
| Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM | 1 |
| Pár, A; Pár, G | 1 |
| Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH | 1 |
| Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T | 1 |
| Burkemper, NM; Chappell, JA; Semchyshyn, N | 1 |
| Mendizabal, M; Reddy, KR | 1 |
| Bruera, G; Giordano, AV; Lapecorella, M; Lucchesi, A; Mariani, G; Napolitano, M; Ricevuto, E; Tudini, M | 1 |
| Finn, RS | 1 |
| Chamalidou, E; Chelis, L; Deftereos, S; Kakolyris, S; Maltezos, E; Ntinos, N; Souftas, V; Xenidis, N | 1 |
| Bruix, J; Sherman, M | 1 |
| Bae, SH; Guan, S; Lim, HY; Park, HC; Seong, J; Tak, WY; Tanaka, M; Zeng, ZC | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, EH; Kim, SU; Lee, DY; Park, JY; Park, MS; Seong, J | 1 |
| Cao, L; Li, B; Li, YM; Sui, CJ; Yin, ZF; Zhang, XF; Zhou, YM | 1 |
| Dogan, E; Koca, D; Olmez, A; Yalcin, S | 1 |
4 review(s) available for sorafenib and Hepatitis B
| Article | Year |
|---|---|
Epidemiology, mutational landscape and staging of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Hepatitis B; Humans; Liver Neoplasms; Neoplasm Staging; Non-alcoholic Fatty Liver Disease; Sorafenib | 2021 |
Management of hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; Incidence; Liver Neoplasms; Mass Screening; Niacinamide; Palliative Care; Phenylurea Compounds; Population Surveillance; Quality of Life; Sorafenib; Viral Hepatitis Vaccines | 2015 |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
3 trial(s) available for sorafenib and Hepatitis B
| Article | Year |
|---|---|
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carcinoma, Hepatocellular; China; Disease Progression; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Sorafenib; Time Factors; Young Adult | 2021 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Asia; B7-H1 Antigen; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Nivolumab; Sorafenib; Treatment Outcome; Young Adult | 2019 |
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
28 other study(ies) available for sorafenib and Hepatitis B
| Article | Year |
|---|---|
MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Hepatitis B; Humans; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Sorafenib | 2023 |
Africa Guidelines for Hepatocellular Carcinoma Buildup Process.
Topics: Africa; Carcinoma, Hepatocellular; Hepatitis B; Humans; Liver Neoplasms; Sorafenib | 2023 |
Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2019 |
CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemokine CCL22; Drug Resistance, Neoplasm; Hep G2 Cells; Hepatitis B; Humans; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Receptors, CCR4; Signal Transduction; Sorafenib; T-Lymphocytes; Tumor Burden | 2020 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult | 2017 |
The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fibroblast Growth Factor 4; Hepatectomy; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate | 2018 |
Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Rats, Sprague-Dawley; Sorafenib; Young Adult | 2018 |
Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Interferon-gamma; Interleukin-4; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Th2 Cells | 2019 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss | 2013 |
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nucleosides; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Reduction Behavior; Sorafenib; Survival Rate | 2015 |
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Prospective Studies; Risk Factors; Sorafenib; Survival Analysis; Terminology as Topic | 2015 |
Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
Topics: Age Factors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hepatitis B; Hepatitis B virus; Incidence; Liver Neoplasms; Male; Mice; Mice, Transgenic; Niacinamide; Orchiectomy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Signal Transduction; Sorafenib; Trans-Activators; Viral Regulatory and Accessory Proteins | 2015 |
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hepatitis B; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Proto-Oncogene Proteins c-raf; Recurrence; Retrospective Studies; Sorafenib | 2016 |
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Hepatitis B; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Niacinamide; Phenylurea Compounds; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2016 |
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Female; Hepatitis B; Humans; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; Sorafenib | 2017 |
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib | 2008 |
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2009 |
Localized dyskeratotic plaque with milia associated with sorafenib.
Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepatitis B; Humans; Keratosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor VIII; Hemophilia A; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Drug therapy: sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Factors; Sorafenib | 2010 |
Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
Topics: Aged; Antiretroviral Therapy, Highly Active; Benzenesulfonates; Carcinoma, Hepatocellular; Coinfection; Drug Synergism; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis C; Hepatitis, Autoimmune; Humans; Liver Neoplasms; Mass Screening; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography | 2011 |
Multidisciplinary management of nonresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatitis B; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Republic of Korea; ROC Curve; Sorafenib; Treatment Outcome; Young Adult | 2012 |
MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma.
Topics: Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; DNA-Binding Proteins; Gene Expression Regulation; Hepatitis B; Humans; Immunohistochemistry; Liver Neoplasms; Minichromosome Maintenance Complex Component 7; Multivariate Analysis; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2012 |
Clinicopathological characteristics of hepatocellular carcinoma in Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; alpha-Fetoproteins; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Factors; Sorafenib; Turkey; Young Adult | 2012 |